Clinical

March 2, 2021
By Elise Mak
Ascletis joins Madrigal and Viking in global race for THR-β agonist for NASH
Liver disease specialist Ascletis Pharma Inc. said its nonalcoholic steatohepatitis (NASH)-focused subsidiary, Gannex Pharma Co. Ltd., will start global development of its oral THR-β agonist, ASC-41, after it obtained an IND approval from the FDA based on positive phase I data generated in China.
March 2, 2021
By Randy Osborne
Neurocrine schizophrenia thesis intact post-Interact? Opinions differ on phase II data
San Diego-based Neurocrine Biosciences Inc.’s good-and-bad top-line phase II data with d-amino acid oxidase inhibitor luvadaxistat, also known NBI-1065844 and TAK-831, in schizophrenia likely came as little surprise to many, given earlier experience in the general pathway.
March 2, 2021
In the clinic for March 2, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aileron, Avadel, Biomx, Cerecor, Clearside, Gemoab, Highlight, Hoth, Inovio, Kymera, Eurocrine, Neurosense, NGM, Orbus, Pipeline, Scynexis, Seres.

Ascletis joins Madrigal and Viking in global race for THR-β agonist for NASH